Apart from TMB, Programmed cell death ligand 1 and ligand 2 (PD-L1 and PD-L2) and microsatellite instable (MSI) associated mismatch repair genes in tumor samples were identified as significant biomarkers to predict patients’ responses to immunotherapy. This evidence concerns the gene CD274 and neoplasm.